[go: up one dir, main page]

WO2008109686A3 - Non- infectious recombinant virus-like particles and their pharmaceutical applications - Google Patents

Non- infectious recombinant virus-like particles and their pharmaceutical applications Download PDF

Info

Publication number
WO2008109686A3
WO2008109686A3 PCT/US2008/055936 US2008055936W WO2008109686A3 WO 2008109686 A3 WO2008109686 A3 WO 2008109686A3 US 2008055936 W US2008055936 W US 2008055936W WO 2008109686 A3 WO2008109686 A3 WO 2008109686A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
virus
vlps
interferons
vlp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/055936
Other languages
French (fr)
Other versions
WO2008109686A2 (en
WO2008109686A8 (en
Inventor
Igor Sivov
Dmitry Kulish
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEUROK PHARMA LLC
Original Assignee
NEUROK PHARMA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2007138092/13A external-priority patent/RU2007138092A/en
Application filed by NEUROK PHARMA LLC filed Critical NEUROK PHARMA LLC
Publication of WO2008109686A2 publication Critical patent/WO2008109686A2/en
Publication of WO2008109686A3 publication Critical patent/WO2008109686A3/en
Publication of WO2008109686A8 publication Critical patent/WO2008109686A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24223—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to novel virus-like particles (VLPs), including those based on Hepatitis C virus (HCV), as well as methods for their recombinant production and their use for stimulation of immunity and treatment of human and animal diseases. More specifically, the invention relates to novel synthetic constructs allowing the production of the novel recombinant non-infectious VLP ISVAC built of structural proteins of Hepatitis C virus (HCV), which VLP is efficiently produced in cultured BHK21 cells using the replication machinery of foot-and-mouth disease virus (FMDV). The pharmaceutical VLP preparations of the invention are highly efficient inducers of (i) endogenous Type I interferons (TYPE-I-IFN) such as interferon-q together with the general pool of interferons and (ii) general humoral immune response through stimulation of B cells (B-lymphocytes). VLPs of the invention are useful in treatment of human and animal diseases that can be treated by induction of interferons and/or B cell stimulation, including, e.g., hepatitis C, hepatitis B, FMD and certain malignancies, as well as asthmatic disorders, and allergies. VLPs of the invention are also useful as adjuvants that stimulate patient immune response to antigens and as viral diagnostic tools.
PCT/US2008/055936 2007-03-05 2008-03-05 Non- infectious recombinant virus-like particles and their pharmaceutical applications Ceased WO2008109686A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
RU2007108037 2007-03-05
RU2007108037 2007-03-05
RU2007138092 2007-10-16
RU2007138092/13A RU2007138092A (en) 2007-10-16 2007-10-16 NON-INFECTIOUS RECOMBINANT PSEUDOVIRIONES OF THE HEPATITIS VIRUS C "ISVAK" TM, THEIR APPLICATION AS A MEANS FOR TREATMENT AND PREVENTION OF DISEASES, SYSTEMS OF DELIVERY OF BIOLOGICALLY INACTIVE ANTIVASIS

Publications (3)

Publication Number Publication Date
WO2008109686A2 WO2008109686A2 (en) 2008-09-12
WO2008109686A3 true WO2008109686A3 (en) 2009-03-12
WO2008109686A8 WO2008109686A8 (en) 2009-07-30

Family

ID=39591928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/055936 Ceased WO2008109686A2 (en) 2007-03-05 2008-03-05 Non- infectious recombinant virus-like particles and their pharmaceutical applications

Country Status (1)

Country Link
WO (1) WO2008109686A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011000058A1 (en) * 2009-07-03 2011-01-06 The University Of Queensland A method of preparation of a biological particulate structure
CN104995299B (en) * 2012-12-11 2020-02-28 宝生物工程株式会社 expression cassette
WO2016006658A1 (en) * 2014-07-10 2016-01-14 タカラバイオ株式会社 Production method for non-enveloped virus particles
CN108367066B (en) * 2015-09-10 2023-08-11 台湾地区“中央研究院” Avian influenza vaccine compositions comprising viroids and novel adjuvants
US20230040417A1 (en) * 2019-12-03 2023-02-09 The Council Of The Queensland Institute Of Medical Research Defective interfering particles
CN111303251B (en) * 2020-02-25 2021-07-30 中国农业科学院兰州兽医研究所 A method for in vitro assembly of foot-and-mouth disease virus-like particles and its application
CN117050158B (en) * 2023-10-10 2023-12-29 云南农业大学 Application of red mouth gull IFN-gamma gene and recombinant protein encoded by same

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050071A1 (en) * 1997-05-01 1998-11-12 Chiron Corporation Use of virus-like particles as adjuvants
US5846795A (en) * 1985-03-07 1998-12-08 Mycogen Plant Science, Inc. RNA transformation vector
WO2004061110A1 (en) * 2003-01-05 2004-07-22 Obschestvo S Ogranichennoi Otvetstvennostiju 'genno-Inzhenernye Tekhnologii 2000' Complementation method for producing rna-containing virus-like particles of hepatotropic viruses
WO2005005614A2 (en) * 2003-07-03 2005-01-20 Pecos Labs, Inc. Combined b-cell and t-cell epitopes on vlp for improved vaccines
WO2005014110A1 (en) * 2003-07-22 2005-02-17 Cytos Biotechnology Ag Cpg-packaged liposomes
US7049428B1 (en) * 1998-03-04 2006-05-23 Washington University HCV variants

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846795A (en) * 1985-03-07 1998-12-08 Mycogen Plant Science, Inc. RNA transformation vector
WO1998050071A1 (en) * 1997-05-01 1998-11-12 Chiron Corporation Use of virus-like particles as adjuvants
US7049428B1 (en) * 1998-03-04 2006-05-23 Washington University HCV variants
WO2004061110A1 (en) * 2003-01-05 2004-07-22 Obschestvo S Ogranichennoi Otvetstvennostiju 'genno-Inzhenernye Tekhnologii 2000' Complementation method for producing rna-containing virus-like particles of hepatotropic viruses
WO2005005614A2 (en) * 2003-07-03 2005-01-20 Pecos Labs, Inc. Combined b-cell and t-cell epitopes on vlp for improved vaccines
WO2005014110A1 (en) * 2003-07-22 2005-02-17 Cytos Biotechnology Ag Cpg-packaged liposomes

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
GRGACIC ET AL: "Virus-like particles: Passport to immune recognition", METHODS : A COMPANION TO METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC., NEW YORK, NY, US, vol. 40, no. 1, 1 September 2006 (2006-09-01), pages 60 - 65, XP005660384, ISSN: 1046-2023 *
GRUBMAN M J ET AL: "Foot-and-mouth disease", CLINICAL MICROBIOLOGY REVIEWS, WASHINGTON, DC, US, vol. 17, no. 2, 1 April 2004 (2004-04-01), pages 465 - 493, XP002996189, ISSN: 0893-8512 *
JEONG SOOK-HYANG ET AL: "Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates", JOURNAL OF VIROLOGY, vol. 78, no. 13, July 2004 (2004-07-01), pages 6995 - 7003, XP002502301, ISSN: 0022-538X *
KUNDIG ET AL: "Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY - YEARLY BOOK, INC, US, vol. 117, no. 6, 1 June 2006 (2006-06-01), pages 1470 - 1476, XP005470419, ISSN: 0091-6749 *
NDJOMOU ET AL: "Development and characterization of a recombinant cDNA-based hepatitis C virus system", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 359, no. 1, 2 June 2007 (2007-06-02), pages 57 - 62, XP022103142, ISSN: 0006-291X *
PINTO LIGIA A ET AL: "CELLULAR IMMUNE RESPONSES TO HUMAN PAPILLOMAVIRUS (HPV)-16 L1 IN HEALTHY VOLUNTEERS IMMUNIZED WITH RECOMBINANT HPV-16 L1 VIRUS-LIKE PARTICLES", JOURNAL OF INFECTIOUS DISEASES, CHICAGO, IL, vol. 188, no. 2, 15 July 2003 (2003-07-15), pages 327 - 338, XP008069504, ISSN: 0022-1899 *
QIAO M ET AL: "HEPATITIS C VIRUS-LIKE PARTICLES COMBINED WITH NOVEL ADJUVANT SYSTEMS ENHANCE VIRUS-SPECIFIC IMMUNE RESPONSES", HEPATOLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 37, no. 1, 1 January 2003 (2003-01-01), pages 52 - 59, XP009020356, ISSN: 0270-9139 *
SAILAJA ET AL: "Human immunodeficiency virus-like particles activate multiple types of immune cells", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 362, no. 2, 5 May 2007 (2007-05-05), pages 331 - 341, XP022065065, ISSN: 0042-6822 *
SANTI ET AL: "Virus-like particles production in green plants", METHODS : A COMPANION TO METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC., NEW YORK, NY, US, vol. 40, no. 1, 1 September 2006 (2006-09-01), pages 66 - 76, XP005660385, ISSN: 1046-2023 *
YANG RONGEUN ET AL: "B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88", JOURNAL OF IMMUNOLOGY, vol. 174, no. 12, June 2005 (2005-06-01), pages 7912 - 7919,7904, XP002502300, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
WO2008109686A2 (en) 2008-09-12
WO2008109686A8 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
WO2008109686A3 (en) Non- infectious recombinant virus-like particles and their pharmaceutical applications
MX2007003171A (en) Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide.
JP2015501840A5 (en)
WO2008034388A8 (en) Virus-like particles of capsid proteins from human papillomavirus type 16/58/18/6/11 and the method for preparation and the uses thereof
BR112014015016A8 (en) HOMODIMERIC PROTEIN OF TWO IDENTICAL AMINO ACID CHAINS, AMINO ACID CHAIN, NUCLEIC ACID MOLECULE, PHARMACEUTICAL COMPOSITION, HOST CELL, METHOD OF PREPARATION OF A HOMODIMERIC PROTEIN, METHOD FOR PREPARING A VACCINE, VACCINE AND METHOD OF TREATMENT OR PREVENTION
RU2019107976A (en) VACCINE COMPOSITION
CN102166356A (en) Application of alpha-mannatide as vaccine adjuvant and vaccine preparation prepared using same
Krishnaveni A review on transfer factor an immune modulator
CN103687942A (en) Virus-like particles and process for preparing same
JP2010506926A5 (en)
DE60332377D1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES MEDIATED BY THE HUMANE PAPILLOMA VIRUS
WO2005068639A3 (en) Particle-induced ghrelin immune response
CN106421774B (en) PreS1 is used to prepare hepatitis B vaccine and treats the purposes of chronic hepatitis B
Lu et al. Enhanced protective immune response of foot-and-mouth disease vaccine through DNA-loaded virus-like particles
CN103893748A (en) Novel vaccine for hand-foot-and-mouth disease and a preparation method thereof
TW200509964A (en) VP1 of foot-and-mouth disease virus
CN103320451A (en) Genetic engineering protein vaccine for preventing EV71, and preparation method thereof
CN102266551B (en) Interleukin-4 therapeutic vaccine that can be used to treat human or animal immune-related diseases
CN102199217A (en) Hepatitis B virus multi-epitope fusion protein and preparation method and application thereof
CN102018964A (en) Three-plasmid co-immune vaccine system capable of breaking immune tolerance and preparation method thereof
Albalaty et al. SARS-CoV-2 vaccines from A to Z: A review of the current challenges
CN115925823A (en) T cell epitope polypeptide FAFPFTIYSL derived from SARS-CoV-2 encoding protein and application thereof
He et al. Combination adjuvants enhance recombinant H5 hemagglutinin vaccine protection against high-dose viral challenge in chickens
CN103505725B (en) Universal influenza vaccine with broad-spectrum cross protection capability and preparation method thereof
CN102038951A (en) Nucleic acid vaccine adjuvant designed based on MCP-1 and construction method thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08731455

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WPC Withdrawal of priority claims after completion of the technical preparations for international publication

Ref document number: 2007108037

Country of ref document: RU

Date of ref document: 20090902

Free format text: WITHDRAWN AFTER TECHNICAL PREPARATION FINISHED

122 Ep: pct application non-entry in european phase

Ref document number: 08731455

Country of ref document: EP

Kind code of ref document: A2